Login / Signup

Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3.

Matilde de Las RivasEarnest James Paul DanielYoshiki NarimatsuIsmael CompañónKentaro KatoPablo HermosillaAurélien ThureauLaura Ceballos-LaitaHelena CoelhoPau BernadóFilipa MarceloLars HansenRyota MaedaAnabel LostaoFrancisco CorzanaHenrik ClausenThomas A GerkenRamon Hurtado Guerrero
Published in: Nature chemical biology (2020)
Polypeptide GalNAc-transferase T3 (GalNAc-T3) regulates fibroblast growth factor 23 (FGF23) by O-glycosylating Thr178 in a furin proprotein processing motif RHT178R↓S. FGF23 regulates phosphate homeostasis and deficiency in GALNT3 or FGF23 results in hyperphosphatemia and familial tumoral calcinosis. We explored the molecular mechanism for GalNAc-T3 glycosylation of FGF23 using engineered cell models and biophysical studies including kinetics, molecular dynamics and X-ray crystallography of GalNAc-T3 complexed to glycopeptide substrates. GalNAc-T3 uses a lectin domain mediated mechanism to glycosylate Thr178 requiring previous glycosylation at Thr171. Notably, Thr178 is a poor substrate site with limiting glycosylation due to substrate clashes leading to destabilization of the catalytic domain flexible loop. We suggest GalNAc-T3 specificity for FGF23 and its ability to control circulating levels of intact FGF23 is achieved by FGF23 being a poor substrate. GalNAc-T3's structure further reveals the molecular bases for reported disease-causing mutations. Our findings provide an insight into how GalNAc-T isoenzymes achieve isoenzyme-specific nonredundant functions.
Keyphrases
  • molecular dynamics
  • density functional theory
  • stem cells
  • single cell
  • computed tomography
  • early onset
  • magnetic resonance
  • structural basis
  • mass spectrometry
  • single molecule
  • amino acid
  • replacement therapy